Showing results (61-70 of 73) with videos related to
Sort By:
Pageof 8
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 20, 2008
Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myelomaDeborah J Heath, Andrew D Chantry, Clive H Buckle, et al.European Cytokine Network|September 22, 2001
Quantitation of chemokines (MDC, TARC) expression in mucosa from Crohn's disease and ulcerative colitisF Jugde, M Alizadeh, C Boissier, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 24, 2019
TGFβ Inhibition Stimulates Collagen Maturation to Enhance Bone Repair and Fracture Resistance in a Murine Myeloma ModelAlanna C Green, Darren Lath, Katie Hudson, et al.Journal of Immunology (Baltimore, Md. : 1950)|June 22, 2000
Macrophage-derived chemokine and EBI1-ligand chemokine attract human thymocytes in different stage of development and are produced by distinct subsets of medullary epithelial cells: possible implications for negative selectionF Annunziato, P Romagnani, L Cosmi, et al.Blood|May 1, 1997
Cloning and characterization of exodus, a novel beta-chemokineR Hromas, P W Gray, D Chantry, et al.Stem Cells (Dayton, Ohio)|February 28, 2012
A small molecule modulator of prion protein increases human mesenchymal stem cell lifespan, ex vivo expansion, and engraftment to bone marrow in NOD/SCID miceSindhu T Mohanty, Claire J Cairney, Andrew D Chantry, et al.Journal of Leukocyte Biology|July 17, 1998
Profile of human macrophage transcripts: insights into macrophage biology and identification of novel chemokinesD Chantry, A J DeMaggio, H Brammer, et al.Blood|February 9, 2000
KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cellsJ T Stine, C Wood, M Hill, et al.Cytometry. Part B, Clinical Cytometry|December 20, 2018
Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter-laboratory study: Is it ready for primetime use?Stuart D Scott, Matthew Fletcher, Helen Whitehouse, et al.Oncogene|June 12, 2020
The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myelomaLisa J Crawford, David C Campbell, Jonathan J Morgan, et al.Pageof 8